Literature DB >> 21828344

Are quality improvements in the get with the guidelines: stroke program related to better care or better data documentation?

Mathew J Reeves1, Maria V Grau-Sepulveda, Gregg C Fonarow, Daiwai M Olson, Eric E Smith, Lee H Schwamm.   

Abstract

BACKGROUND- Increased compliance with performance measures could reflect better care or better data documentation. We examined trends in the documentation of eligibility criteria, treatment contraindications, and missing data in the Get With The Guidelines-Stroke program to quantify their contribution to increased performance measure compliance. METHODS AND RESULTS- Data on 569 883 ischemic stroke admissions to 1028 GWTG-Stroke hospitals between April 2003 and September 2009 were obtained. Seven measures were examined: intravenous recombinant tissue plasminogen activator therapy, early antithrombotics, deep vein thrombosis prophylaxis, anticoagulants for atrial fibrillation/flutter, discharge antithrombotics, lipid therapy, and smoking cessation. Within each target population, the proportion of subjects treated, not treated, not treated because of contraindications, or with missing data were generated by calendar year. There were minimal changes in the size of the target populations for 6 of the measures; however, the size of the deep vein thrombosis prophylaxis population was reduced ≈5% in 2008 because of a format change to the data collection form. All measures showed significant increases in the proportion of eligible subjects treated across the study period. These increases occurred without major shifts in contraindications or missing data, with the exception of anticoagulation for atrial fibrillation/flutter where the increase occurred in conjunction with a decline in contraindications. Similar findings were seen when the data were examined by the duration of hospital participation in the program. CONCLUSIONS- These findings suggest that the majority of performance improvement in the Get With The Guidelines-Stroke program represent an increase in the number of patients with stroke treated and not changes to the underlying target populations or documentation of contraindications or missing data.

Entities:  

Mesh:

Year:  2011        PMID: 21828344     DOI: 10.1161/CIRCOUTCOMES.111.961755

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  14 in total

1.  Predictors of increased intravenous tissue plasminogen activator use among hospitals participating in the Massachusetts Primary Stroke Service Program.

Authors:  Natalia S Rost; Eric E Smith; Muhammad A Pervez; Philip Mello; Paul Dreyer; Lee H Schwamm
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-04-24

2.  Presentation, Evaluation, Management, and Outcomes of Acute Stroke in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.

Authors:  Rasha Khatib; Yurany A Arevalo; Mark A Berendsen; Shyam Prabhakaran; Mark D Huffman
Journal:  Neuroepidemiology       Date:  2018-07-19       Impact factor: 3.282

Review 3.  Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.

Authors:  Daniel T Lackland; Edward J Roccella; Anne F Deutsch; Myriam Fornage; Mary G George; George Howard; Brett M Kissela; Steven J Kittner; Judith H Lichtman; Lynda D Lisabeth; Lee H Schwamm; Eric E Smith; Amytis Towfighi
Journal:  Stroke       Date:  2013-12-05       Impact factor: 7.914

4.  Association of Get With The Guidelines-Stroke Program Participation and Clinical Outcomes for Medicare Beneficiaries With Ischemic Stroke.

Authors:  Sarah Song; Gregg C Fonarow; DaiWai M Olson; Li Liang; Phillip J Schulte; Adrian F Hernandez; Eric D Peterson; Mathew J Reeves; Eric E Smith; Lee H Schwamm; Jeffrey L Saver
Journal:  Stroke       Date:  2016-04-14       Impact factor: 7.914

5.  The University of Texas Houston Stroke Registry (UTHSR): implementation of enhanced data quality assurance procedures improves data quality.

Authors:  Mohammad H Rahbar; Nicole R Gonzales; Manouchehr Ardjomand-Hessabi; Amirali Tahanan; Melvin R Sline; Hui Peng; Renganayaki Pandurengan; Farhaan S Vahidy; Jessica D Tanksley; Ayodeji A Delano; Rene M Malazarte; Ellie E Choi; Sean I Savitz; James C Grotta
Journal:  BMC Neurol       Date:  2013-06-15       Impact factor: 2.474

6.  Comparison of performance achievement award recognition with primary stroke center certification for acute ischemic stroke care.

Authors:  Gregg C Fonarow; Li Liang; Eric E Smith; Mathew J Reeves; Jeffrey L Saver; Ying Xian; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm
Journal:  J Am Heart Assoc       Date:  2013-10-14       Impact factor: 5.501

7.  Participation in Get With The Guidelines-Stroke and Its Association With Quality of Care for Stroke.

Authors:  George Howard; Lee H Schwamm; John P Donnelly; Virginia J Howard; Adam Jasne; Eric E Smith; J David Rhodes; Brett M Kissela; Gregg C Fonarow; Dawn O Kleindorfer; Karen C Albright
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

8.  Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry.

Authors:  Steven R Messé; Pooja Khatri; Mathew J Reeves; Eric E Smith; Jeffrey L Saver; Deepak L Bhatt; Maria V Grau-Sepulveda; Margueritte Cox; Eric D Peterson; Gregg C Fonarow; Lee H Schwamm
Journal:  Neurology       Date:  2016-09-14       Impact factor: 9.910

9.  The association between socioeconomic status and disability after stroke: findings from the Adherence eValuation After Ischemic stroke Longitudinal (AVAIL) registry.

Authors:  Janet Prvu Bettger; Xin Zhao; Cheryl Bushnell; Louise Zimmer; Wenqin Pan; Linda S Williams; Eric D Peterson
Journal:  BMC Public Health       Date:  2014-03-26       Impact factor: 3.295

10.  Stroke Severity Is a Crucial Predictor of Outcome: An International Prospective Validation Study.

Authors:  Natalia S Rost; Alex Bottle; Jin-Moo Lee; Marc Randall; Steven Middleton; Louise Shaw; Vincent Thijs; Gabriel J E Rinkel; Thomas M Hemmen
Journal:  J Am Heart Assoc       Date:  2016-01-21       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.